Verrica Pharmaceuticals
VRCA
79 hedge funds and large institutions have $21.6M invested in Verrica Pharmaceuticals in 2024 Q3 according to their latest regulatory filings, with 19 funds opening new positions, 24 increasing their positions, 16 reducing their positions, and 14 closing their positions.
1,044% more call options, than puts
Call options by funds: $103K | Put options by funds: $9K
50% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 16
36% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 14
7% more funds holding
Funds holding: 74 → 79 (+5)
0.9% less ownership
Funds ownership: 4.4% → 3.49% (-0.9%)
84% less capital invested
Capital invested by funds: $136M → $21.6M (-$114M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$1.45M |
| 2 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$1.04M |
| 3 |
ECM
ExodusPoint Capital Management
New York
|
+$838K |
| 4 |
Renaissance Technologies
New York
|
+$461K |
| 5 |
Morgan Stanley
New York
|
+$436K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACA
Avoro Capital Advisors
New York
|
-$29.2M |
| 2 |
Invesco
Atlanta,
Georgia
|
-$3.09M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$2.14M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$817K |
| 5 |
KCM
Kornitzer Capital Management
Shawnee Mission,
Kansas
|
-$541K |
VRCA Hedge Fund Activity: Q3 2024 in Review
79 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Verrica Pharmaceuticals (VRCA) for Q3 2024, worth a combined $21.6M — down 84% from $136M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new VRCA positions and 14 closed out — a net gain of 5 holders — while 24 added to existing stakes and 16 trimmed.
The largest buyer was Qube Research & Technologies (QRT), opening a new position worth an estimated $1.45M. The largest seller was Avoro Capital Advisors, exiting entirely with an estimated $29.2M sold.
- 79 institutional investors held Verrica Pharmaceuticals (VRCA) as of Q3 2024, up from 74 in Q2 2024.
- Funds reported $21.6M of Verrica Pharmaceuticals stock for Q3 2024, down 84% quarter-over-quarter.
- 19 funds opened new Verrica Pharmaceuticals positions in Q3 2024 and 14 closed out, a net change of +5 holders.
- The largest Verrica Pharmaceuticals buyer in Q3 2024 was Qube Research & Technologies (QRT), an estimated $1.45M added.
- The largest Verrica Pharmaceuticals seller in Q3 2024 was Avoro Capital Advisors, an estimated $29.2M sold.
Based on aggregated 13F filings for Q3 2024.